Avandia (rosiglitazone) increases the risk of heart attack
June 2007
Patients are asking about the news that Avandia (rosiglitazone) increases the risk of heart attack.
A new meta-analysis suggests a higher risk of heart attacks in patients taking rosiglitazone compared to other meds or placebo.
Experts crunching the same numbers come up with differing conclusions, and point out the study's shortcomings. The complicated statistics are explored in our Detail-Document.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote